Peripheral neuropathy
Conditions
Interventions
Herbal medicine group:Wen-luo-tong
Control group:Placebo
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with malignant tumor diagnosed by pathology or cytology; 2.PN=1(NCI-CTCAE V5.0) induced by chemotherapy/target therapy 3.Aged 18 to 80 years; 4.ECOG score: 0-2; 5.Estimated survival period=3 months; 6.No major organ dysfunction, heart, liver, kidney function is normal, laboratory indicators to achieve the following requirements:neutrophils>1.5×10^9/L; platelet90g/L; bilirubin is normal or<1.5×ULN; AST/ALT<2.5×ULN; Serum creatinine<1.5×ULN, endogenous creatinine clearance (CCR)=60 ml/min (calculated by Cockcroft-gault formula); 7.Able to understand the situation of this study, be able to coordinate with the assessment of PN grading, and have signed the informed consent.
Exclusion criteria
Exclusion criteria: 1.Diagnosed with PN induced by other original disease, such as diabetes induced PN, etc.); 2.Diagnosed with other skin disease, such as hand-foot syndrome induced by Xelox(Oxaliplatin+capecitabine)chemotherapy; 3.Received other medication that may affect PN; 4.Has serious, uncontrolled organic lesions or infections; 5.Pregnant or lactating women; 6.Currently or within 4 weeks of participating in other clinical trials; 7.A clear neurological and psychiatric history, including dementia that may affect understanding and informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total effective rate of PN; | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptom remission rate;Quality of life;Sensory nerve function;Efficacy of anticancer therapy; | — |
Countries
China
Contacts
Public ContactDeng Bo
China-Japan Friendship Hospital
Outcome results
None listed